Citigroup’s Blueprint Medicines BPMC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-154,048
| Closed | -$19.7M | – | 6100 |
|
|
2025
Q2 | $19.7M | Sell |
154,048
-150,790
| -49% | -$15.7M | 0.01% | 963 |
|
|
2025
Q1 | $27M | Buy |
304,838
+209,656
| +220% | +$20.5M | 0.01% | 820 |
|
|
2024
Q4 | $8.3M | Sell |
95,182
-48,259
| -34% | -$4.42M | ﹤0.01% | 1522 |
|
|
2024
Q3 | $13.3M | Buy |
143,441
+23,189
| +19% | +$2.3M | 0.01% | 1180 |
|
|
2024
Q2 | $13M | Buy |
120,252
+16,389
| +16% | +$1.64M | 0.01% | 1113 |
|
|
2024
Q1 | $9.85M | Sell |
103,863
-74,794
| -42% | -$6.41M | 0.01% | 1260 |
|
|
2023
Q4 | $16.5M | Buy |
178,657
+107,205
| +150% | +$6.95M | 0.01% | 965 |
|
|
2023
Q3 | $3.59M | Buy |
71,452
+10,985
| +18% | +$587K | ﹤0.01% | 1609 |
|
|
2023
Q2 | $3.82M | Sell |
60,467
-87,840
| -59% | -$4.78M | ﹤0.01% | 1675 |
|
|
2023
Q1 | $6.67M | Buy |
148,307
+60,988
| +70% | +$2.75M | ﹤0.01% | 1341 |
|
|
2022
Q4 | $3.83M | Sell |
87,319
-13,257
| -13% | -$636K | ﹤0.01% | 1619 |
|
|
2022
Q3 | $6.63M | Buy |
100,576
+12,672
| +14% | +$814K | ﹤0.01% | 1381 |
|
|
2022
Q2 | $4.44M | Buy |
87,904
+64,922
| +282% | +$3.8M | ﹤0.01% | 1596 |
|
|
2022
Q1 | $1.47M | Sell |
22,982
-40,179
| -64% | -$2.88M | ﹤0.01% | 2606 |
|
|
2021
Q4 | $6.76M | Buy |
63,161
+4,056
| +7% | +$424K | ﹤0.01% | 1631 |
|
|
2021
Q3 | $6.08M | Sell |
59,105
-3,293
| -5% | -$307K | ﹤0.01% | 1683 |
|
|
2021
Q2 | $5.49M | Buy |
62,398
+18,064
| +41% | +$1.66M | ﹤0.01% | 1824 |
|
|
2021
Q1 | $4.31M | Buy |
44,334
+30,032
| +210% | +$3M | ﹤0.01% | 1883 |
|
|
2020
Q4 | $1.6M | Buy |
14,302
+7,684
| +116% | +$810K | ﹤0.01% | 3069 |
|
|
2020
Q3 | $614K | Sell |
6,618
-29,188
| -82% | -$2.25M | ﹤0.01% | 3683 |
|
|
2020
Q2 | $2.79M | Sell |
35,806
-5,076
| -12% | -$343K | ﹤0.01% | 2423 |
|
|
2020
Q1 | $2.39M | Buy |
40,882
+18,513
| +83% | +$1.19M | ﹤0.01% | 2315 |
|
|
2019
Q4 | $1.79M | Sell |
22,369
-4,992
| -18% | -$374K | ﹤0.01% | 3113 |
|
|
2019
Q3 | $2.01M | Sell |
27,361
-45,926
| -63% | -$3.97M | ﹤0.01% | 2863 |
|
|
2019
Q2 | $6.91M | Buy |
73,287
+46,556
| +174% | +$3.84M | 0.01% | 1692 |
|
|
2019
Q1 | $2.14M | Sell |
26,731
-114,863
| -81% | -$8.49M | ﹤0.01% | 2574 |
|
|
2018
Q4 | $7.63M | Sell |
141,594
-40,076
| -22% | -$2.44M | 0.01% | 1467 |
|
|
2018
Q3 | $14.2M | Sell |
181,670
-11,434
| -6% | -$795K | 0.01% | 1057 |
|
|
2018
Q2 | $12.3M | Buy |
193,104
+192,478
| +30,747% | +$15.3M | 0.01% | 1136 |
|
|
2018
Q1 | $57K | Buy |
626
+263
| +72% | +$22.7K | ﹤0.01% | 6055 |
|
|
2017
Q4 | $27K | Sell |
363
-29,032
| -99% | -$2.04M | ﹤0.01% | 6561 |
|
|
2017
Q3 | $2.05M | Sell |
29,395
-6,553
| -18% | -$350K | ﹤0.01% | 2635 |
|
|
2017
Q2 | $1.82M | Buy |
35,948
+22,536
| +168% | +$957K | ﹤0.01% | 2684 |
|
|
2017
Q1 | $536K | Sell |
13,412
-52,442
| -80% | -$1.88M | ﹤0.01% | 3818 |
|
|
2016
Q4 | $1.85M | Buy |
65,854
+59,443
| +927% | +$1.79M | ﹤0.01% | 3043 |
|
|
2016
Q3 | $190K | Buy |
6,411
+93
| +1% | +$2.31K | ﹤0.01% | 4697 |
|
|
2016
Q2 | $128K | Sell |
6,318
-5,033
| -44% | -$91.5K | ﹤0.01% | 4876 |
|
|
2016
Q1 | $205K | Sell |
11,351
-73,812
| -87% | -$1.28M | ﹤0.01% | 5069 |
|
|
2015
Q4 | $2.24M | Buy |
85,163
+8,668
| +11% | +$195K | ﹤0.01% | 2402 |
|
|
2015
Q3 | $1.63M | Buy |
76,495
+76,350
| +52,655% | +$2.11M | ﹤0.01% | 2639 |
|
|
2015
Q2 | $4K | Buy |
+145
| New | +$4.14K | ﹤0.01% | 6842 |
|
Other funds holding BPMC
IA
HNB
Citigroup's BPMC Position: Q3 2025 in Review
Citigroup sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 154,048 shares — an estimated $19.7M sold.
Citigroup first reported a position in BPMC in Q2 2015 and held it in 41 quarters. The position peaked at $27M in Q1 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.
- Citigroup reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
- Citigroup sold 154,048 Blueprint Medicines shares in Q3 2025, an estimated $19.7M.
- Citigroup first reported a position in Blueprint Medicines in Q2 2015 and held it in 41 quarters.
- Citigroup's Blueprint Medicines position peaked at $27M in Q1 2025.
- 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.
Based on Citigroup's 13F filing for Q3 2025, filed 10 Nov 2025.